Vertex jumps after positive Phase 3 interim data for povetacicept in IgA nephropathy

Vertex Pharmaceuticals (VRTX) is up 8.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The stock appears to be rallying after Vertex released positive interim Phase 3 results for povetacicept in IgA nephropathy, a kidney disease with meaningful commercial potential. Investors likely viewed the magnitude of proteinuria reduction, broad endpoint success, and tolerability profile as improving the probability of a faster regulatory path.

Details:

Vertex announced that a pre-specified Week 36 interim analysis of its Phase 3 RAINIER trial in IgA nephropathy met the primary endpoint and key secondary endpoints.

In the interim analysis population, povetacicept achieved a 52.0% reduction from baseline in urine protein-to-creatinine ratio (UPCR), with a 49.8% reduction versus placebo (statistically significant).

The company stated the drug was generally safe and well tolerated in the trial, with no drug-related serious adverse events or deaths reported in the release.

Vertex has previously indicated that, if interim results were positive, they could support an accelerated-approval filing strategy, alongside a rolling submission approach and use of a priority review voucher to shorten review time.

Sources:

Business Wire, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VRTX Insider Trading Activity

$VRTX insiders have traded $VRTX stock on the open market 61 times in the past 6 months. Of those trades, 0 have been purchases and 61 have been sales.

Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:

JEFFREY M LEIDEN (Executive Chairman) has made 0 purchases and 17 sales selling 137,073 shares for an estimated $60,942,656.
AMIT SACHDEV (EVP Chief Patient & Ext Af Off) has made 0 purchases and 9 sales selling 60,459 shares for an estimated $28,377,385.
CHARLES F JR WAGNER (EVP, CO & FO) has made 0 purchases and 3 sales selling 23,532 shares for an estimated $10,778,252.
OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) has made 0 purchases and 7 sales selling 12,203 shares for an estimated $5,725,801.
JONATHAN BILLER (EVP and Chief Legal Officer) has made 0 purchases and 7 sales selling 8,619 shares for an estimated $4,076,426.
EDWARD MORROW III ATKINSON (EVP, Chief Technical Ops. Off.) has made 0 purchases and 5 sales selling 7,767 shares for an estimated $3,598,634.
DUNCAN MCKECHNIE (EVP, Chief Commercial Officer) has made 0 purchases and 3 sales selling 7,347 shares for an estimated $3,552,671.
MARK E. BUNNAGE (EVP, Chief Scientific Officer) has made 0 purchases and 4 sales selling 6,260 shares for an estimated $2,984,769.
CARMEN BOZIC (EVP and CMO) sold 2,329 shares for an estimated $1,118,641
KRISTEN AMBROSE (SVP & Chief Accounting Officer) has made 0 purchases and 3 sales selling 1,956 shares for an estimated $914,567.
JOY LIU (EVP and Chief Legal Officer) sold 892 shares for an estimated $442,396
SANGEETA N. BHATIA sold 266 shares for an estimated $133,000

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$VRTX Hedge Fund Activity

We have seen 794 institutional investors add shares of $VRTX stock to their portfolio, and 775 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 8,547,690 shares (-74.0%) from their portfolio in Q4 2025, for an estimated $3,875,180,738
PARNASSUS INVESTMENTS, LLC removed 1,648,433 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $747,333,584
BLACKROCK, INC. added 1,498,942 shares (+6.7%) to their portfolio in Q4 2025, for an estimated $679,560,345
VICTORY CAPITAL MANAGEMENT INC added 1,109,200 shares (+49.4%) to their portfolio in Q4 2025, for an estimated $502,866,912
FMR LLC removed 1,091,172 shares (-33.0%) from their portfolio in Q4 2025, for an estimated $494,693,737
WELLINGTON MANAGEMENT GROUP LLP removed 950,311 shares (-19.9%) from their portfolio in Q4 2025, for an estimated $430,832,994
WINSLOW CAPITAL MANAGEMENT, LLC added 887,640 shares (+inf%) to their portfolio in Q4 2025, for an estimated $402,420,470

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$VRTX Congressional Stock Trading

Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:

REPRESENTATIVE DAVID TAYLOR sold up to $15,000 on 01/29.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$VRTX Analyst Ratings

Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/13/2026
Bernstein issued a "Outperform" rating on 01/12/2026
Leerink Partners issued a "Outperform" rating on 12/29/2025
Wells Fargo issued a "Overweight" rating on 12/10/2025
UBS issued a "Buy" rating on 11/07/2025
Citigroup issued a "Buy" rating on 10/02/2025
Evercore ISI Group issued a "Outperform" rating on 09/11/2025

To track analyst ratings and price targets for $VRTX, check out Quiver Quantitative's $VRTX forecast page.

$VRTX Price Targets

Multiple analysts have issued price targets for $VRTX recently. We have seen 17 analysts offer price targets for $VRTX in the last 6 months, with a median target of $541.0.

Here are some recent targets:

Eliana Merle from Barclays set a target price of $607.0 on 02/17/2026
Whitney Ijem from Canaccord Genuity set a target price of $441.0 on 02/17/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $591.0 on 02/17/2026
Brian Abrahams from RBC Capital set a target price of $541.0 on 02/13/2026
Jay Olson from Oppenheimer set a target price of $540.0 on 02/13/2026
Paul Matteis from Stifel set a target price of $466.0 on 02/13/2026
Greg Harrison from Scotiabank set a target price of $558.0 on 02/13/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.